SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs10836235

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol (TACTIC) Trial

Breast cancer patients undergoing trastuzumab-based HER2-directed therapy are at risk of heart function decline or heart failure symptoms, but it is unknown if, when, and for how long cardiovascular protective strategies, e.g. with a beta-blocker, could help. This study randomly assigns those taking curative-intent trastuzumab-based HER2-directed therapy to the beta-blocker carvedilol—either when significant heart function decline or subtle early signs of heart injury (either by elevation of a cardiac blood biomarker, i.e. cardiac troponin, or by an abnormal heart ultrasound marker, i.e. global longitudinal strain) are noted, or preventatively before beginning trastuzumab-based HER2-directed therapy. This study will further randomly assign those patients on carvedilol to either discontinuation at the end of trastuzumab-based HER2-directed therapy or continuation for another year, providing much needed clinical trial data on what the best strategy ("tactic") for those at risk of cardiotoxicity with trastuzumab-based HER2-directed therapy is.

NCT03879629 Breast Cancer Drug: Carvedilol
MeSH:Cardiomyopathies
HPO:Cardiomyopathy

Correlation of absolute delta change in GLS and LVEF while on trastuzumab and after stopping trastuzumab with the frequency of the following SNPs: trastuzumab-related: p<1x10-5 hits from Norton GWAS (six loci) 130 HER 2 Ile665Val, HER2 Pro1170Ala125, 126, 130, anthracycline-related: ABCB1 rs1128503, ABCB4 rs1149222, ABCC1 rs45511401, ABCC2 res17222723, CAT rs10836235, CBR3 rs1056892, CYBA rs4673, CYP3A4*22 rs35599367, NCF4 rs1883112, RAC2 rs13058338, RARG rs2229774, SLC28A3 rs7853758, TOP2B rs10865801, and UGT 1A6*4 rs1786378374, 150-152, beta-blocker-related: β2-AR Gln27Gln, β1-AR Arg389Arg 80-82 and CYP2D6 polymorphisms (CYP2D6 alleles (*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *15, *17, *19, *20, *29, *35, *36, *40 and *41), as well as 7 CYP2D6 gene duplications (*1 9 N, *2 9 N, *4 9 N, *10 9 N, *17 9 N, *35 9 N and *41 9 N) by use of the AmpliChip CYP450 GeneChip.

Primary Outcomes

Description: Incidence of heart failure or asymptomatic decline in left-ventricular ejection fraction (LVEF) by >10% in patients whose LVEF is ≥50% or LVEF drop ≥5% in those with a decrease to <50% (primary outcome measure)

Measure: Rate of asymptomatic and symptomatic cardiac dysfunction

Time: 1 year

Description: Reversible LVEF decline to within 5% of baseline (secondary primary outcome measure)

Measure: Rate of reversible cardiac function decline

Time: 1 year

Secondary Outcomes

Description: Delta change in LVEF from completion to one year after completion of trastuzumab-based HER2-directed therapy

Measure: Cardiac function changes after completion of HER2-directed therapy

Time: 1 year

Description: Correlation of absolute delta change in GLS and LVEF while on trastuzumab and after stopping trastuzumab with the frequency of the following SNPs: trastuzumab-related: p<1x10-5 hits from Norton GWAS (six loci) 130 HER 2 Ile665Val, HER2 Pro1170Ala125, 126, 130, anthracycline-related: ABCB1 rs1128503, ABCB4 rs1149222, ABCC1 rs45511401, ABCC2 res17222723, CAT rs10836235, CBR3 rs1056892, CYBA rs4673, CYP3A4*22 rs35599367, NCF4 rs1883112, RAC2 rs13058338, RARG rs2229774, SLC28A3 rs7853758, TOP2B rs10865801, and UGT 1A6*4 rs1786378374, 150-152, beta-blocker-related: β2-AR Gln27Gln, β1-AR Arg389Arg 80-82 and CYP2D6 polymorphisms (CYP2D6 alleles (*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *15, *17, *19, *20, *29, *35, *36, *40 and *41), as well as 7 CYP2D6 gene duplications (*1 9 N, *2 9 N, *4 9 N, *10 9 N, *17 9 N, *35 9 N and *41 9 N) by use of the AmpliChip CYP450 GeneChip

Measure: Gene variants and risk of cardiotoxicity and response to therapy

Time: 2 years


HPO Nodes


HP:0001638: Cardiomyopathy
Genes 730
NDUFS1 LIMK1 LIPT1 TTR MPLKIP MICOS13 INSR NEB CPT2 TNNT2 PSEN1 FKRP LMNA KCNAB2 MYH7 SGSH FANCL EPB42 LAMP2 CSRP3 SLC22A5 TSFM LMNA ND2 TNNI3 RAF1 GPC3 PEX7 ELN NDUFS8 EYA4 TNNI3 PDGFRA MLX BRIP1 PCCB GMPPB KRAS ECHS1 TPI1 NDUFS7 NDUFAF1 NDUFV2 GBE1 RRM2B BOLA3 MRPS14 SMC1A SYNE2 MRPL44 HAMP TRNT1 LIMS2 NRAS SHOC2 DOLK HCCS HADH DMD GLA ND4 TMEM43 NDUFS3 DMD PET100 NDUFV2 TNNT2 RAF1 NDUFAF2 LMNA FHL1 SHOC2 AGK HSD17B10 TNNI3 TRNQ TRNK SDHB XYLT2 TTPA AGK HRAS SCO2 NDUFS2 FHL2 NDUFB11 RNF113A TNNT2 MYBPC3 SYNE1 MRAP TRNT XRCC4 ACTN2 VPS33A DLD BSCL2 BBS2 KCNH1 CRYAB PHYH MYSM1 SLX4 PCCA VCL AGL GPC4 TOP3A INSR TIMMDC1 NDUFAF8 NDUFB10 TMEM70 COX3 LMNA LMNA ACADVL SARDH COX8A BRAF TREX1 DES SLC19A2 LMNA HGSNAT MLYCD PEX1 COQ4 DES TPM2 SLC25A20 TCAP LAMA4 FANCA DMD WFS1 ATP5F1D LAMA2 TMPO NDUFS6 TNNT2 ARSB TNNC1 FOXRED1 NDUFV1 PTPN11 FKTN NBAS DMD SKI LAMB3 NDUFA11 LAMP2 SLC25A4 SELENON FOXRED1 XRCC2 UBR1 NDUFAF4 LMNA FOS CISD2 JPH2 HFE RBM20 MMP1 GNPTAB RNASEH2B LDB3 GMPPB IGF2 PPARG UBE2T SDHA FKRP PRKAG2 SLC25A4 AGPAT2 DSP PPA2 TNNI3 ATAD3A CLN3 PLN TRNS1 GNE ANK1 PMM2 TPM1 GTF2IRD1 ND5 PEX16 TPM1 PPARG TWNK HADHA TRNH NDUFS8 SDHD NDUFAF3 FANCB PEX11B LIAS TMEM126B MYOZ2 HNRNPA2B1 SLC19A3 PCCB DPM3 STAR SGCB PEX5 NDUFS2 MYH7 MYLK2 GSN FANCM RFC2 ERCC4 SDHAF1 MYPN HAND2 POLG ACTA1 COX6B1 PCCA MEN1 PEX12 RAF1 GPC4 CRYAB RAF1 COX14 FHL1 GATAD1 NDUFA12 RYR2 MYH6 TMEM43 POMGNT1 NEBL ANKRD11 NEB NDUFS8 ITPA POMT1 MAP2K2 PTPN11 TAF1A ACTC1 RBM20 CLIP2 PYGM XYLT1 FKTN POMK COA5 XK ALG1 DPM3 MIB1 GLB1 COA3 SCN5A TMEM70 ERCC3 NDUFS2 ENPP1 NDUFV1 JUP NEU1 MGME1 GTPBP3 DMPK CAP2 TNNC1 ADAR CHKB BRCA2 PEX19 LAMC2 IFIH1 COX1 MRPL3 WFS1 AIP TMEM126B MYPN MYL2 DSC2 ND5 HBB BRCA1 FKTN SCO2 MYH6 TPM3 MYH7 IDUA GSN ND6 EPG5 PTPN11 RRM2B SDHD POLG TARS1 POMT2 ALMS1 FLNC BMP2 COX15 TRNL1 HJV HMGCL DMD MAD2L2 ACTA1 RYR1 TERT AHCY GATA4 NUP107 NDUFAF2 COX15 KCNQ1OT1 SLC25A3 NDUFA10 BCS1L TRNL1 RNU4ATAC RMRP POMT1 SLC4A1 LTBP4 TANGO2 NDUFA10 ACAD8 BRAF ND3 CAV1 MYPN RNASEH2C ABCC9 CPT2 TK2 TRNW MTFMT CPT1A NDUFB3 ND6 CDKN1C NDUFA2 TKFC ABCC6 SUFU PIGT COX2 NDUFAF3 COX20 PYGL MYH7 ACTN2 ACAD9 ADCY5 USP9X CSRP3 NDUFA4 SGCD BSCL2 KCNQ1 DOLK TPM3 MGME1 TPM2 RAF1 DSG2 BAG3 SOS1 H19-ICR HAMP TAPT1 FTO ACTC1 NDUFA9 HADHB MAP2K1 DSP ERBB3 COL7A1 PMM2 SLC25A4 FLNC TGFB3 TNNI3 TRNL1 POMT1 PRKAG2 COL7A1 MTO1 PALB2 GPC3 NDUFS7 FKRP AARS2 FANCE RNU4ATAC TNNT2 SCO1 TRIP4 ADCY5 PRDM16 NDUFAF6 NDUFAF5 PPP1CB HNRNPA1 MYO18B SPTB PGM1 GATA5 NDUFB8 LAMA4 FKTN ANKRD1 DTNA RFWD3 KRAS ELAC2 ABCC6 TACO1 MYBPC3 TRNF ALMS1 TAZ PARS2 SGCA CPT2 NDUFA13 ND3 SURF1 TCAP HADHA COG7 COX7B CPT2 PET100 LAMA3 GTF2H5 GMPPB MYOT PRDM16 MRPS22 TXNRD2 COX7B PHYH GYS1 CENPE HADH PEX26 HFE COQ2 GNS NPPA ND1 SLC25A20 ATPAF2 KLHL41 DCAF8 WARS2 TTN PSEN2 TPM1 TRNE ND1 GATAD1 SYNE2 SELENON FANCF SAMHD1 NAXD COX10 PEX7 C1QBP VCL GPR101 PEX3 NAGA PRDM16 MMUT RAB3GAP2 EYA4 DES FIG4 GTF2E2 NDUFS1 IDH2 SGCB JUP TNNC1 FANCG RERE PSEN1 PKP2 TNNI3 NAGLU COA8 KRAS SDHA AIP TAZ NDUFAF5 RNASEH1 ATP6 FXN NUP107 HLA-B FANCI KAT6B ACADL TWNK HADHA PEX13 FANCD2 POLG TPM2 SDHAF1 ABCC9 MYH7 MYH6 PNPLA2 POLG ACTA1 MYH7 SLC2A10 GTPBP3 TFR2 DSG2 MAP2K1 TWNK POLG2 MYL3 BAZ1B FLAD1 TRNS2 ND1 NDUFS4 FLNC ABHD5 HACD1 TXNRD2 PPCS ITGA7 NDUFB11 SDHA TRNK PEX2 TRNN NEK8 PPCS ACAD9 PLN DSG2 COA8 MYH7 CLPB RMND1 CAVIN1 MIPEP DSP MYOT NDUFAF4 COA6 TMEM126A RAD51 VPS33A LDB3 TAZ TTN TACO1 CRYAB TWNK MMUT ANO5 SLC25A4 RIT1 BAG3 FAH TTR ACADS IDUA YARS2 TRNS1 SDHA RBCK1 GTF2I EMD MAP2K1 ANKS6 EPG5 HRAS PIGT HADHB MC2R MAP2K2 CRYAB NDUFV2 MYBPC3 KBTBD13 TPM3 PSEN2 GNPTAB HJV BRAF IL12B SPEG PEX6 SLC30A10 NAGA GJA5 NDUFA6 SURF1 SCN5A D2HGDH UQCRFS1 NF1 LMNA MYPN VPS13A ATAD3A NNT RAD51C ACTC1 TKFC LMNA CDH23 NDUFS4 DNAJC19 TNNI3K LMNA NDUFA2 KLF1 JUP BRAF KCNJ8 TRNW TTN ALG1 LDB3 NDUFA1 ERCC2 GYG1 PDHA1 NDUFA11 LMNA HPS1 SDHA AIP LDB3 CAV3 MYL2 SGCD ATP6 NEXN CSRP3 NDUFAF1 NDUFS3 FIG4 NDUFS2 FANCC ND4 NDUFS4 FBXL4 DNAJC19 OPA1 PLN SLC40A1 ATP6V1A PEX10 TBL2 FHL1 PEX14 PRKAG2 HCCS SPTA1 DLD AHCY VCL DES SLC25A3 VCP ACADVL TRNK DSP MYPN PEX7 GABRD ABCC9 VAC14 ND2 FHL1 AGPAT2 FOXRED1 ATP5F1E POLG HADHA NDUFB9 ACTA1 RNASEH2A KIF20A DSP FXN TRNV POMT2 NDUFB11 JUP TTN IDUA NDUFB11 ACAD8 NEXN MAP3K20 MYH6 PNPLA2 POMT1 TGFB1 NEXN USP8 GUSB BAG3 NUBPL